Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Kimihiko Yanagita"'
Autor:
Taiga Otsuka, Shunya Nakashita, Kimihiko Yanagita, Keisuke Ario, Hiroaki Kawasoe, Seiji Kawazoe, Yuichiro Eguchi, Toshihiko Mizuta
Publikováno v:
Diseases, Vol 3, Iss 2, Pp 68-77 (2015)
Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who
Externí odkaz:
https://doaj.org/article/7915344b4090486b897d19ee9ffc3666
Autor:
Nobuyuki Yamashita, Aritsune Ooho, Shinji Shimoda, Hideyuki Nomura, Chie Morita, Jun Hayashi, Yasunori Ichiki, Eiji Kajiwara, Eiichi Ogawa, Koichi Azuma, Toshimasa Koyanagi, Takeaki Satoh, Makoto Nakamuta, Kimihiko Yanagita, Naoki Yamashita, Masami Kuniyoshi, Kazuhiro Takahashi, Akira Kawano, Kazufumi Dohmen, Norihiro Furusyo, Masaki Kato, Rie Sugimoto
Publikováno v:
Journal of Gastroenterology and Hepatology. 37:371-377
BACKGROUND AND AIM Direct-acting antivirals (DAAs) have contributed to the improvement of outcomes for all patients with chronic hepatitis C. The aim of this study was to evaluate the long-term hepatic benefits of hepatitis C virus (HCV) cure by DAAs
Autor:
Eiji Kajiwara, Takeaki Satoh, Makoto Nakamuta, Kazuhiro Takahashi, Koichi Azuma, Toshimasa Koyanagi, Masami Kuniyoshi, Jun Hayashi, Kazufumi Dohmen, Aritsune Ooho, Chie Morita, Norihiro Furusyo, Hideyuki Nomura, Kimihiko Yanagita, Akira Kawano, Eiichi Ogawa, Shinji Shimoda, Hiromasa Amagase, Yasunori Ichiki, Rie Sugimoto, Masaki Kato
Publikováno v:
The Journal of Infectious Diseases. 226:431-440
Background Direct-acting antiviral (DAA) treatment has revolutionized hepatitis C virus (HCV) care. We aimed to evaluate the risk for the development of hepatocellular carcinoma (HCC) in patients aged 75–84 years with chronic hepatitis C after HCV
Autor:
Eiichi Ogawa, Nomura Hideyuki, Makoto Nakamuta, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Aritsune Ooho, Koichi Azuma, Kazuhiro Takahashi, Takeaki Satoh, Toshimasa Koyanagi, Yasunori Ichiki, Masami Kuniyoshi, Kimihiko Yanagita, Hiromasa Amagase, Chie Morita, Rie Sugimoto, Masaki Kato, Shinji Shimoda, Jun Hayashi
Publikováno v:
Journal of Hepatology. 73:S610-S611
Autor:
Kimihiko Yanagita, Yoshihiko Maehara, Shinichi Aishima, Tetsuhiro Fukahori, Yoshinao Oda, Tomohiro Iguchi, Motoyuki Yamagata, Eiji Tsujita, Takashi Sonoda
Publikováno v:
Molecular and Clinical Oncology. 5:599-603
Malignant transformation of hepatocellular adenoma (HA) is relatively rare and has been reported to be associated with dysregulation of the β-catenin pathway. The presence of bone marrow metaplasia in HA is an uncommon histological characteristic. T
Autor:
Hideyuki Nomura, Koichi Azuma, Toshimasa Koyanagi, Chie Morita, Akira Kawano, Aritsune Ooho, Hiromasa Amagase, Masaki Kato, Kazufumi Dohmen, Yasunori Ichiki, Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, Rie Sugimoto, Kazuhiro Takahashi, Kimihiko Yanagita, Shinji Shimoda, Masami Kuniyoshi, Takeaki Satoh, Makoto Nakamuta, Eiji Kajiwara
Publikováno v:
Cancers
Cancers, Vol 12, Iss 2602, p 2602 (2020)
Volume 12
Issue 9
Cancers, Vol 12, Iss 2602, p 2602 (2020)
Volume 12
Issue 9
Advanced fibrosis/cirrhosis and related biomarkers have been recognized as useful predictors of the development of hepatocellular carcinoma (HCC) by patients with chronic hepatitis C (CHC) following hepatitis C virus (HCV) cure by direct-acting antiv
Autor:
Akira Kawano, Hideyuki Nomura, Kazuhiro Takahashi, Kimihiko Yanagita, Chie Morita, Kazufumi Dohmen, Shinji Shimoda, Hiromi Ishibashi, Koichiro Miki, Yasunori Ichiki, Hirohisa Shigematsu
Publikováno v:
Internal Medicine
Objective Interferon-free regimens of direct-acting antiviral agents have improved the treatment response for chronic hepatitis C virus (HCV) infection, and improvement in the serum albumin level during interferon-free therapy has been reported. The
Autor:
Yuichiro Eguchi, Hiroaki Kawasoe, Seiji Kawazoe, Keisuke Ario, Shunya Nakashita, Taiga Otsuka, Kimihiko Yanagita, Toshihiko Mizuta
Publikováno v:
Diseases
Diseases, Vol 3, Iss 2, Pp 68-77 (2015)
Volume 3
Issue 2
Pages 68-77
Diseases, Vol 3, Iss 2, Pp 68-77 (2015)
Volume 3
Issue 2
Pages 68-77
Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who
Autor:
Shinji Iwane, Yasushi Ide, Kimihiko Yanagita, Taiga Otsuka, Tsutomu Yasutake, Takanori Kumagai, Yuichiro Eguchi, Seiji Kawazoe, Takumi Akiyama, Toshihiko Mizuta, Yasunori Kawaguchi, Iwata Ozaki
Publikováno v:
Internal Medicine. 54:2551-2560
Objective This study evaluated the efficacy and safety of triple therapy with telaprevir (TVR), pegylated interferon α-2b (PegIFN-α-2b) and ribavirin (RBV) in Japanese patients chronically infected with hepatitis C virus (HCV) genotype 1b in real-w
Autor:
Rie Sugimoto, Masami Kuniyoshi, Takeaki Satoh, Makoto Nakamuta, Eiichi Ogawa, Chie Morita, Aritsune Ooho, Kimihiko Yanagita, Eiji Kajiwara, Akira Kawano, Koichi Azuma, Toshimasa Koyanagi, Kazuhiro Takahashi, Hiromasa Amagase, Kazufumi Dohmen, Masaki Kato, Jun Hayashi, Shinji Shimoda, Yasunori Ichiki, Nomura Hideyuki, Norihiro Furusyo
Publikováno v:
Journal of Hepatology. 70:e745